OR WAIT null SECS
© 2022 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
June 27, 2022
ImmunoGen has formed a research collaboration with Oxford BioTherapeutics to develop novel antibody-drug conjugates for cancers with high unmet needs.
May 15, 2022
The author describes how to seize market opportunities while navigating the requirements of both drug therapies and delivery devices.
May 04, 2022
The two companies signed an exclusive collaboration agreement for the Aidaptus auto-injector.
February 11, 2022
Piramal Pharma Solutions plans to construct a multipurpose ADC manufacturing and aseptic fill/finish facility in Grangemouth, Scotland, and to upgrades its existing API manufacturing facility in Morpeth, England.
October 15, 2021
Experts share best practices in designing, manufacturing, and scaling up dry powder inhaler and metered dose inhaler drug–device combination products for inhalation drug delivery.
November 20, 2019
Trends affecting primary pharmaceutical packaging include the shift to more complex drug-device combination products.
October 03, 2019
The contraceptive is expected to receive new chemical entity designation from FDA, giving it patent protection beyond 2030. It will be launched in early 2021, pending FDA approval.
June 20, 2019
The company has expanded its high-potency API capability at its Riverview, MI, facility to serve the growing antibody drug conjugates market.
June 02, 2019
A simple, one-part DPI aims to make inhalation drug treatment more accessible and affordable.
August 01, 2018
API can be mixed with silicone and other polymers to create drug-delivery combination products.